



(51) International Patent Classification:

C07K 16/18 (2006.01) A61P 37/00 (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/EP2022/074260

(22) International Filing Date:

31 August 2022 (31.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21193927.7 31 August 2021 (31.08.2021) EP

(71) Applicant: AARHUS UNIVERSITET [DK/DK]; Nordre Ringgade 1, 8000 Aarhus C (DK).

(72) Inventors: LAURSEN, Nick Stub; c/o Aarhus Universitet, Nordre Ringgade 1, 8000 Aarhus C (DK). PEDERSEN,


Henrik; c/o Aarhus Universitet, Nordre Ringgade 1, 8000 Aarhus C (DK). JENSEN, Rasmus Kjeldsen; c/o Aarhus Universitet, Nordre Ringgade 1, 8000 Aarhus C (DK). ANDERSEN, Gregers Rom; c/o Aarhus Universitet, Nordre Ringgade 1, 8000 Aarhus C (DK).

(74) Agent: MATHYS & SQUIRE; The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: FUSION PROTEINS COMPRISING ANTI C3B ANTIBODIES FOR COMPLEMENT REGULATION

Fig. 1



(57) Abstract: The present application relates to a fusion protein comprising: an antibody or antigen-binding fragment thereof that binds to C3b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) the amino acid sequences according to SEQ ID NO: 11 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 11; and (ii) the amino acid sequences according to SEQ ID NO: 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12, wherein the antibody or antigen-binding fragment thereof of the fusion protein does not compete for binding to C3b with the polypeptide of the fusion protein. The application also provides polypeptides, nucleic acids, vectors and methods of preparing these as well as methods of treatment and pharmaceutical compositions.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*